Shanghai Pharma may bid $4 billion to acquire StadaArzneimittel, a German generic drugmaker. Stada has already accepted a similar offer from a consortium formed by two private equity firms -- Bain and Cinven. However, Shanghai Pharma has until June 8 to make an offer at a higher price. One of the problems with Shanghai Pharma's entry would be Beijing, which recently introduced restrictions on foreign investment. Shanghai Pharma may team up with European PE fund, Advent, or some other PE firm. Earlier, FosunPharma considered making a bid for Stada, though it is no longer in contention.
Source: ChinaBio Today
Please to leave a comment.